scholarly journals Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

2016 ◽  
Vol 6 (3) ◽  
pp. e410-e410 ◽  
Author(s):  
X Papanikolaou ◽  
A Rosenthal ◽  
M Dhodapkar ◽  
J Epstein ◽  
R Khan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Prognostic Factor ◽  
Monoclonal Gammopathies ◽  
Subset Analysis ◽  
Major Prognostic Factor

Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1164-1164
Author(s):  
David Dingli ◽  
Grzegorz S. Nowakowski ◽  
Angela Dispenzieri ◽  
Martha Q. Lacy ◽  
Suzanne R. Hayman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Stem Cell ◽  
Prognostic Factor ◽  
Response To Therapy ◽  
Independent Prognostic Factor ◽  
High Dose ◽  
Rapid Progression ◽  
Myeloma Cells ◽  
The Impact

Abstract Background: The presence of circulating myeloma cells (CMC) detected by flow cytometry at the time of diagnosis of multiple myeloma is associated with a shortened response to therapy and reduced overall survival (OS). We hypothesized that the presence of CMC at the time of stem cell collection prior to high dose therapy (HDT) and autologous stem cell transplantation (ASCT) would identifies a cohort of patients with a high risk of rapid progression. Methods: The Mayo Clinic myeloma transplant database was queried for patients who were mobilized using cyclophosphamide and hematopoietic growth factors. CMC was determined using flow cytometry by gating on a population of CD38 bright and CD45 negative cells. The impact of CMC on OS and time to progression (TTP) and its role in the context of established prognostic parameters was evaluated. Results: Of 246 patients with MM undergoing ASCT, 95 had CMC. Patients with CMC had significantly higher plasma cell labeling index, adverse cytogenetics, B2-M and resistant disease. Complete response (CR) rates post transplant were 32% and 36% for patients with and without CMC (p=0.5034). OS was 33.2 and 58.6 months (p=0.0052) while TTP was 14.1 and 22 months respectively (p=0.0005). Figure Figure On multivariate analysis, CMC remained an independent prognostic factor in a model that included cytogenetics and disease status at time of transplant (p=0.0314). A prognostic system based on the presence or absence of CMC and karyotype abnormalities was developed. Patients with neither, one or both parameters had a median, OS of 55, 48 and 21.5 months respectively (p<0.0001) while TTP was 22, 15.4 and 6.5 months for the same groups (p<0.0001). Conclusion: The presence of CMC at the time of HDT and ASCT is an independent prognostic factor. The combination of CMC and cytogenetics provides a simple yet powerful scoring system that stratifies patients and guides their management.

Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.

1985 ◽  
Vol 3 (11) ◽  
pp. 1503-1507 ◽  
Author(s):  
M Boccadoro ◽  
A Gallamini ◽  
A Fruttero ◽  
P Gavarotti ◽  
V Redoglia ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Prognostic Factor ◽  
Plasma Cell ◽  
Patient Survival ◽  
Labeling Index ◽  
Survival Duration ◽  
Monoclonal Gammopathies ◽  
Thymidine Labeling Index ◽  
Cell Acid

Plasma cell acid phosphatase (AP) activity and thymidine labeling index (LI%) were evaluated concomitantly in 52 patients with monoclonal gammopathies. AP score, percentage of AP positive plasma cells, and LI% were significantly higher in 26 patients with multiple myeloma (MM) at the time of diagnosis than in 11 monoclonal gammopathy of undetermined significance (MGUS) and eight smoldering myeloma (SM) patients. LI% had the highest statistical correlation with disease status. A 1% cutoff could clearly separate the patients with progressive MM compared to those with stable disease (SM-MGUS) (P less than .001). There was a significant overall correlation between the AP score and LI% (P less than .005). Since LI% is a recognized powerful prognostic factor, this correlation suggests that the AP score can also be a reliable test predicting patient survival duration. In addition, we identified a subgroup of IgG MM patients with very high tumor mass who had a low LI% but a high AP score. This was associated with very poor patient survival and indicated the discrete prognostic importance of AP score in this subgroup with low LI%. Thus, both the LI% and AP score can be recommended as helpful clinical tests in patients with monoclonal gammopathies.

scholarly journals Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood ◽  
2018 ◽  
Vol 132 (23) ◽  
pp. 2456-2464 ◽  
Author(s):  
Aurore Perrot ◽  
Valerie Lauwers-Cances ◽  
Jill Corre ◽  
Nelly Robillard ◽  
Cyrille Hulin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factor ◽  
Minimal Residual Disease ◽  
Deep Sequencing ◽  
Residual Disease ◽  
Prospective Trial ◽  
Excellent Outcome ◽  
Key Points ◽  
Major Prognostic Factor ◽  
Minimal Residual

Key Points MRD using NGS-identified patients with an excellent outcome in multiple myeloma. MRD should be assessed in every prospective trial, and is a candidate to become a primary end point.

Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance

2021 ◽  
Author(s):  
Kenji Nozaki ◽  
Yuki Fujioka ◽  
Daisuke Sugiyama ◽  
Jun Ishikawa ◽  
Masato Iida ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Flow Cytometry Analysis

Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma

2021 ◽  
Author(s):  
Teruhito Takakuwa ◽  
Kensuke Ohta ◽  
Eiji Nakatani ◽  
Tomoki Ito ◽  
Hitomi Kaneko ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factor ◽  
Previously Treated

Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis

2016 ◽  
Vol 59 (7) ◽  
pp. 615-622 ◽  
Author(s):  
B. Trilling ◽  
E. Cotte ◽  
D. Vaudoyer ◽  
S. Isaac ◽  
E. Piaton ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Peritoneal Carcinomatosis ◽  
Cancer Cells ◽  
Major Prognostic Factor

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 8009-8009
Author(s):  
Angela Dispenzieri ◽  
Amrita Y. Krishnan ◽  
Bonnie Arendt ◽  
Surendra Dasari ◽  
Yvonne Adeduni Efebera ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Multiple Testing ◽  
Residual Disease ◽  
Progression Free Survival ◽  
Complete Response ◽  
Independent Effect ◽  
Next Generation ◽  
Different Response

8009 Background: Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses have been associated with better progression free survival (PFS) and overall survival (OS). Serum (SIFE) and urine immunofixation are the currently used markers for biochemical documentation of CR after which marrow is tested for plasma cell clearance. Next generation flow cytometry and sequencing are used to document the presence of minimal residual disease (MRD). Mass spectrometry of blood by MALDI (Mass-Fix) is a new simple, inexpensive, sensitive, and specific means of detecting monoclonal immunoglobulins. To better test the hypothesis that Mass-Fix is superior to existing methodologies to predict for survival outcomes—especially SIFE-- samples from the STAMINA trial (NCT01109004), a trial comparing 3 transplant approaches among patients who have already received induction, were employed. Methods: Five-hundred and seventy-five patients were included. Samples from enrollment post-induction (post-I) and 1-year post enrollment (1YR) were tested when available. Four response parameters were assessed univariately: Mass-Fix, SIFE, complete response, and MRD by next generation flow cytometry. Mass spectrometry spectra were evaluated in a blinded fashion. Complete response was according to the 2006 International Myeloma Working Group criteria. Multivariate Cox proportional hazard models using stepwise regression were developed to explore the independent effect of the different response parameters on PFS and OS and interactions with other risk factors. Results: Of the 4 response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses (Table). Of the 4 post-I measurements, only MRD predicted for PFS; however, Mass-Fix was the only post-I measurement to predict for OS. Of all the 1-year measures, both 1YR Mass-Fix and 1YR MRD positivity predicted for inferior PFS and OS. In models including MRD and Mass-Fix, SIFE and CR were not prognostic for PFS or OS. Conclusions: Mass-Fix is a powerful means to track monoclonal proteins. The full utility of Mass-Fix was not exploited given the absence of a diagnostic sample and the fact that only serum (and not urine) was tested. Despite these limitations, it performed well at pre-induction and at 1 year. Mass-Fix provides a convenient and non-invasive means of predicting for myeloma outcomes. Clinical trial information: NCT01109004. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document